Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
作者信息
Girgis Suzette, Lin Shun Xin Wang, Pillarisetti Kodandaram, Banerjee Arnob, Stephenson Tara, Ma Xuewen, Shetty Shoba, Yang Tong-Yuan, Hilder Brandi W, Jiao Qun, Hanna Brett, Adams Homer C, Sun Yu-Nien, Sharma Amarnath, Smit Jennifer, Infante Jeffrey R, Goldberg Jenna D, Elsayed Yusri
机构信息
Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA.
Janssen Research & Development, Spring House, PA, USA.
出版信息
Target Oncol. 2022 Sep;17(5):609. doi: 10.1007/s11523-022-00904-y.
Abstract
摘要
相似文献
1
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.更正：转化模型预测替雷利珠单抗治疗多发性骨髓瘤的有效治疗剂量范围。
Target Oncol. 2022 Sep;17(5):609. doi: 10.1007/s11523-022-00904-y.
2
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.转化模型预测替西罗莫司单抗治疗多发性骨髓瘤的有效治疗剂量范围。
Target Oncol. 2022 Jul;17(4):433-439. doi: 10.1007/s11523-022-00893-y. Epub 2022 Jun 24.
3
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.特卡昔单抗，一种 B 细胞成熟抗原 × CD3 双特异性抗体，用于治疗复发或难治性多发性骨髓瘤（MajesTEC-1）：一项多中心、开放标签、单臂、1 期研究。
Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10.
4
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.替西妥单抗是一种用于治疗多发性骨髓瘤的、可重定向T细胞的抗B细胞成熟抗原双特异性抗体。
Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393.
5
Teclistamab in patients with multiple myeloma and impaired renal function.替雷利珠单抗治疗肾功能受损的多发性骨髓瘤患者。
Am J Hematol. 2023 Nov;98(11):E322-E324. doi: 10.1002/ajh.27063. Epub 2023 Aug 23.
6
A BCMA-Targeted Bispecific Antibody Is Active in Multiple Myeloma.一种靶向BCMA的双特异性抗体在多发性骨髓瘤中具有活性。
Cancer Discov. 2021 Oct;11(10):2366. doi: 10.1158/2159-8290.CD-RW2021-119. Epub 2021 Aug 20.
7
Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting.美国社区肿瘤环境中多发性骨髓瘤患者的达雷妥尤单抗使用情况及成本分析。
Future Oncol. 2022 Jan;18(3):301-309. doi: 10.2217/fon-2021-1072. Epub 2021 Oct 28.
8
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.PK/PD 模型分析用于指导伊沙妥昔单抗单药及联合治疗多发性骨髓瘤患者的剂量选择。
CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):928-940. doi: 10.1002/psp4.12666. Epub 2021 Jul 8.
9
MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.骨髓微小残留病灶检测在多发性骨髓瘤中的应用：现代精准治疗的主要未来驱动因素。
Semin Hematol. 2018 Jan;55(1):44-50. doi: 10.1053/j.seminhematol.2018.03.001. Epub 2018 Mar 5.
10
Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant.自体造血干细胞移植后多发性骨髓瘤患者来那度胺维持剂量的安全性和耐受性。
J Oncol Pharm Pract. 2022 Oct;28(7):1613-1616. doi: 10.1177/10781552221112320. Epub 2022 Jul 5.
引用本文的文献
1
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.在中国MajesTEC-1队列的复发/难治性多发性骨髓瘤患者中，替西妥单抗的疗效、安全性和药代动力学。
Cancer. 2025 Jan 1;131(1):e35665. doi: 10.1002/cncr.35665. Epub 2024 Dec 11.
Zotero 插件